Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer With HRR Mutation and MSS
Condition: Gastric Cancer Stage IV Intervention: Drug: olaparib+pembrolizumab+paclitaxel Sponsor: Yonsei University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Research